MTSS1 and neoplasm: The patients with weaker MTSS1 expression displayed improved objective response rates to ICB therapy as compared to those with stronger MTSS1 expression (Fig. 2j, k), corroborating the role of MTSS1 to regulate PD-L1 expression and tumor immune evasion.